HAEM5:High grade B-cell lymphoma with 11q aberrations: Difference between revisions
Jump to navigation
Jump to search
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) Removed old template contents |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}} | {{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Burkitt-Like Lymphoma with 11q Aberration]]. | ||
}}</blockquote> | }}</blockquote> | ||
| Line 39: | Line 40: | ||
|} | |} | ||
==WHO Essential and Desirable Genetic Diagnostic Criteria== | ==WHO Essential and Desirable Genetic Diagnostic Criteria== | ||
<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span> | <span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span> | ||
| Line 181: | Line 85: | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||
The table below represents the smallest reported minimal lost region and smallest reported minimal gain region. Other larger MGR and MLR have been reported.<ref name=":2" /> <ref>{{Cite journal|last=Ferreiro|first=J. F.|last2=Morscio|first2=J.|last3=Dierickx|first3=D.|last4=Marcelis|first4=L.|last5=Verhoef|first5=G.|last6=Vandenberghe|first6=P.|last7=Tousseyn|first7=T.|last8=Wlodarska|first8=I.|date=2015-07-01|title=Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2015.124305|journal=Haematologica|language=en|volume=100|issue=7|pages=e275–e279|doi=10.3324/haematol.2015.124305|issn=0390-6078|pmc=PMC4486241|pmid=25795716}}</ref> | The table below represents the smallest reported minimal lost region and smallest reported minimal gain region. Other larger MGR and MLR have been reported.<ref name=":2">{{Cite journal|last=Salaverria|first=Itziar|last2=Martin-Guerrero|first2=Idoia|last3=Wagener|first3=Rabea|last4=Kreuz|first4=Markus|last5=Kohler|first5=Christian W.|last6=Richter|first6=Julia|last7=Pienkowska-Grela|first7=Barbara|last8=Adam|first8=Patrick|last9=Burkhardt|first9=Birgit|date=2014-02-20|title=A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma|url=https://ashpublications.org/blood/article/123/8/1187/32820/A-recurrent-11q-aberration-pattern-characterizes-a|journal=Blood|language=en|volume=123|issue=8|pages=1187–1198|doi=10.1182/blood-2013-06-507996|issn=0006-4971|pmc=PMC3931189|pmid=24398325}}</ref> <ref>{{Cite journal|last=Ferreiro|first=J. F.|last2=Morscio|first2=J.|last3=Dierickx|first3=D.|last4=Marcelis|first4=L.|last5=Verhoef|first5=G.|last6=Vandenberghe|first6=P.|last7=Tousseyn|first7=T.|last8=Wlodarska|first8=I.|date=2015-07-01|title=Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2015.124305|journal=Haematologica|language=en|volume=100|issue=7|pages=e275–e279|doi=10.3324/haematol.2015.124305|issn=0390-6078|pmc=PMC4486241|pmid=25795716}}</ref> | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 249: | Line 153: | ||
|unknown | |unknown | ||
|- | |- | ||
|5q21.3q32 gain and 6q12.1-q21 loss <ref name=":5">{{Cite journal|last=Asadbeigi|first=Sepideh N.|last2=Deel|first2=Chelsey D.|date=2020-09-08|title=Burkitt-Like Lymphoma with 11q Aberration: A Case Report and Review of a Rare Entity|url=https://www.hindawi.com/journals/crihem/2020/8896322/|journal=Case Reports in Hematology|language=en|volume=2020|pages=e8896322|doi=10.1155/2020/8896322|issn=2090-6560|pmc=PMC7495152|pmid=32963851}}</ref><ref name=":6" /> | |5q21.3q32 gain and 6q12.1-q21 loss <ref name=":5">{{Cite journal|last=Asadbeigi|first=Sepideh N.|last2=Deel|first2=Chelsey D.|date=2020-09-08|title=Burkitt-Like Lymphoma with 11q Aberration: A Case Report and Review of a Rare Entity|url=https://www.hindawi.com/journals/crihem/2020/8896322/|journal=Case Reports in Hematology|language=en|volume=2020|pages=e8896322|doi=10.1155/2020/8896322|issn=2090-6560|pmc=PMC7495152|pmid=32963851}}</ref><ref name=":6">{{Cite journal|last=Gonzalez-Farre|first=Blanca|last2=Ramis-Zaldivar|first2=Joan Enric|last3=Salmeron-Villalobos|first3=Julia|last4=Balagué|first4=Olga|last5=Celis|first5=Verónica|last6=Verdu-Amoros|first6=Jaime|last7=Nadeu|first7=Ferran|last8=Sábado|first8=Constantino|last9=Ferrández|first9=Antonio|date=2019-09|title=Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma|url=http://www.haematologica.org/lookup/doi/10.3324/haematol.2018.207928|journal=Haematologica|language=en|volume=104|issue=9|pages=1822–1829|doi=10.3324/haematol.2018.207928|issn=0390-6078|pmc=PMC6717587|pmid=30733272}}</ref> | ||
|unknown | |unknown | ||
|unknown | |unknown | ||
|unknown | |unknown | ||
|Noted to be recurrently concomitantly present with the characteristic proximal duplications and deletions that define BLL, 11q.<ref name=":5" /> | |Noted to be recurrently concomitantly present with the characteristic proximal duplications and deletions that define BLL, 11q.<ref name=":5" /> | ||
|}Notably, no 1q21 abnormalities were found in myc-negative, 11q positive cases. <ref name=":1" /><ref name=":6" /> | |}Notably, no 1q21 abnormalities were found in myc-negative, 11q positive cases. <ref name=":1">{{Cite journal|last=Horn|first=Heike|last2=Kalmbach|first2=Sabrina|last3=Wagener|first3=Rabea|last4=Staiger|first4=Annette M.|last5=Hüttl|first5=Katrin|last6=Mottok|first6=Anja|last7=Bens|first7=Susanne|last8=Traverse-Glehen|first8=Alexandra|last9=Fontaine|first9=Juliette|date=2021-03|title=A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas|url=https://journals.lww.com/10.1097/PAS.0000000000001613|journal=American Journal of Surgical Pathology|language=en|volume=45|issue=3|pages=356–364|doi=10.1097/PAS.0000000000001613|issn=0147-5185}}</ref><ref name=":6" /> | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
| Line 346: | Line 250: | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
*Conventional cytogenetics (karyotyping) + FISH using MYC break-apart probe to rule out MYC translocation <ref name=":5" /> <ref name=":9" /> | *Conventional cytogenetics (karyotyping) + FISH using MYC break-apart probe to rule out MYC translocation <ref name=":5" /> <ref name=":9">{{Cite journal|last=Kim|first=Jee Ah|last2=M.D|last3=Kim|first3=Hyun-Young|last4=M.D|last5=Kim|first5=Seok Jin|last6=M.D|last7=Kim|first7=Hee-Jin|last8=M.D|last9=Kim|first9=and Sun-Hee|date=2021-11-01|title=A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review|url=https://www.annlabmed.org/journal/view.html?doi=10.3343/alm.2021.41.6.593|journal=Annals of Laboratory Medicine|language=en|volume=41|issue=6|pages=593–597|doi=10.3343/alm.2021.41.6.593|pmc=PMC8203433|pmid=34108287}}</ref> | ||
*Chromosomal microarray analysis <ref name=":6" /> <ref name=":9" /> | *Chromosomal microarray analysis <ref name=":6" /> <ref name=":9" /> | ||
| Line 403: | Line 307: | ||
*Look for 11q aberration if Myc negative lymphoma with morphology reminiscent of BL, DLBCL, or HGBCL <ref name=":6" /> | *Look for 11q aberration if Myc negative lymphoma with morphology reminiscent of BL, DLBCL, or HGBCL <ref name=":6" /> | ||
*Attend to associated chromosomal and mutational abnormalities of other aggressive B-cell lymphomas, ensuring their absence before diagnosis of BLL-11q, since BLL-11q may represent <ref name=":3" /> <ref name=":8" /> <ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rymkiewicz|first3=Grzegorz|last4=Rygier|first4=Jolanta|last5=Malawska|first5=Natalia|last6=Blachnio|first6=Katarzyna|last7=Bystydzienski|first7=Zbigniew|last8=Borysiuk|first8=Anita|last9=Nowakowska|first9=Beata|date=2020-07-01|title=Genetic progression of post-transplant Burkitt-like lymphoma case with 11q-Gain/Loss and MYC amplification|url=https://www.cancergeneticsjournal.org/article/S2210-7762(20)30236-2/abstract|journal=Cancer Genetics|language=English|volume=245|pages=1–5|doi=10.1016/j.cancergen.2020.05.001|issn=2210-7762|pmid=32531723}}</ref> | *Attend to associated chromosomal and mutational abnormalities of other aggressive B-cell lymphomas, ensuring their absence before diagnosis of BLL-11q, since BLL-11q may represent <ref name=":3" /> <ref name=":8">{{Cite journal|last=Wang|first=Jing|last2=Ma|first2=Li|last3=Guo|first3=Jianghong|last4=Xi|first4=Yanfeng|last5=Xu|first5=Enwei|date=2021-03-16|title=Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review|url=https://www.degruyter.com/document/doi/10.1515/med-2021-0246/html|journal=Open Medicine|language=en|volume=16|issue=1|pages=428–434|doi=10.1515/med-2021-0246|issn=2391-5463|pmc=PMC7967281|pmid=33763601}}</ref> <ref>{{Cite journal|last=Grygalewicz|first=Beata|last2=Woroniecka|first2=Renata|last3=Rymkiewicz|first3=Grzegorz|last4=Rygier|first4=Jolanta|last5=Malawska|first5=Natalia|last6=Blachnio|first6=Katarzyna|last7=Bystydzienski|first7=Zbigniew|last8=Borysiuk|first8=Anita|last9=Nowakowska|first9=Beata|date=2020-07-01|title=Genetic progression of post-transplant Burkitt-like lymphoma case with 11q-Gain/Loss and MYC amplification|url=https://www.cancergeneticsjournal.org/article/S2210-7762(20)30236-2/abstract|journal=Cancer Genetics|language=English|volume=245|pages=1–5|doi=10.1016/j.cancergen.2020.05.001|issn=2210-7762|pmid=32531723}}</ref> | ||
*BLL-11q patients treated with R-CHOP (DLBCL treatment) have a higher risk of relapse than those treated with traditional BL treatment <ref name=":5" /> <ref name=":0" /> | *BLL-11q patients treated with R-CHOP (DLBCL treatment) have a higher risk of relapse than those treated with traditional BL treatment <ref name=":5" /> <ref name=":0">{{Cite journal|last=Rymkiewicz|first=Grzegorz|last2=Grygalewicz|first2=Beata|last3=Chechlinska|first3=Magdalena|last4=Blachnio|first4=Katarzyna|last5=Bystydzienski|first5=Zbigniew|last6=Romejko-Jarosinska|first6=Joanna|last7=Woroniecka|first7=Renata|last8=Zajdel|first8=Michalina|last9=Domanska-Czyz|first9=Katarzyna|date=2018-05|title=A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration|url=http://www.nature.com/articles/modpathol2017186|journal=Modern Pathology|language=en|volume=31|issue=5|pages=732–743|doi=10.1038/modpathol.2017.186|issn=0893-3952}}</ref> | ||
Tentatively appears to portend a better prognosis with high likelihood of years of remission <ref name=":6" /> <ref name=":9" /> <ref name=":5" /><ref name=":3" /> | Tentatively appears to portend a better prognosis with high likelihood of years of remission <ref name=":6" /> <ref name=":9" /> <ref name=":5" /><ref name=":3" /> | ||
*100% 2 year event free survival in pediatric cohort<ref name=":4" /> | *100% 2 year event free survival in pediatric cohort<ref name=":4">{{Cite journal|last=Au‐Yeung|first=Rex K. H.|last2=Arias Padilla|first2=Laura|last3=Zimmermann|first3=Martin|last4=Oschlies|first4=Ilske|last5=Siebert|first5=Reiner|last6=Woessmann|first6=Wilhelm|last7=Burkhardt|first7=Birgit|last8=Klapper|first8=Wolfram|date=2020-09|title=Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4 ‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group|url=https://onlinelibrary.wiley.com/doi/10.1111/bjh.16578|journal=British Journal of Haematology|language=en|volume=190|issue=5|pages=753–763|doi=10.1111/bjh.16578|issn=0007-1048}}</ref> | ||
* | * | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases H]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases H]] | |||
<references /> | |||
Revision as of 21:32, 12 February 2025
Haematolymphoid Tumours (WHO Classification, 5th ed.)
 | This page is under construction |
editContent Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition ClassificationThis page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Burkitt-Like Lymphoma with 11q Aberration.
(General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support.)
Primary Author(s)*
Lauren Shealy, MD, Medical University of South Carolina
Daynna Wolff, PhD, Medical University of South Carolina
WHO Classification of Disease
| Structure | Disease |
|---|---|
| Book | Haematolymphoid Tumours (5th ed.) |
| Category | B-cell lymphoid proliferations and lymphomas |
| Family | Mature B-cell neoplasms |
| Type | Large B-cell lymphomas |
| Subtype(s) | High grade B-cell lymphoma with 11q aberrations |
WHO Essential and Desirable Genetic Diagnostic Criteria
(Instructions: The table will have the diagnostic criteria from the WHO book autocompleted; remove any non-genetics related criteria. If applicable, add text about other classification systems that define this entity and specify how the genetics-related criteria differ.)
| WHO Essential Criteria (Genetics)* | |
| WHO Desirable Criteria (Genetics)* | |
| Other Classification |
*Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the WHO Classification of Tumours.
Related Terminology
(Instructions: The table will have the related terminology from the WHO autocompleted.)
| Acceptable | |
| Not Recommended |
Gene Rearrangements
BLL-11q has no known gene fusions at this time.
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
Individual Region Genomic Gain/Loss/LOH
The table below represents the smallest reported minimal lost region and smallest reported minimal gain region. Other larger MGR and MLR have been reported.[1] [2]
| Chr # | Gain / Loss / Amp / LOH | Minimal Region Genomic Coordinates [Genome Build] | Minimal Region Cytoband | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|
| 11 | Loss[3] | chr11: 128,177,670-134,931,948[3] | 11q24.4q25[3] | Yes | unknown | unknown | |
| 11 | Gain[3] | chr11: 117,815,640-119,275,901 [3] | 11q23.3[3] | Yes | unknown | unknown | |
| 11 | minimal duplication
region, 11.95 Mbp[3] |
ch11: 109,285,414-121,236,822 [3] | 11q22.3q24.1[3] | Yes | unknown | unknown | Minimal duplication region contained PAFAH1B2, USP2, and CBL oncogenes.[3] |
Characteristic Chromosomal or Other Global Mutational Patterns
- Research up until this point has revealed no conservative breakpoints. [3]
| Chromosomal Pattern | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|
| proximal 11q duplications range in size | yes | unknown | unknown | The characteristic gains combined with the terminal deletions can occur in the context of myc-positive BL and other myc-negative HGBCLs. The absence of a MYC translocation/amplification in association with this chromosomal pattern is critical to the provisional diagnosis of BLL-11q and may have prognostic and therapeutic implications, which are further discussed below. At least one case has been identified with only proximal gains in the context of UPD.[3] |
| terminal 11q deletions range in size | yes | unknown | unknown | |
| 5q21.3q32 gain and 6q12.1-q21 loss [4][5] | unknown | unknown | unknown | Noted to be recurrently concomitantly present with the characteristic proximal duplications and deletions that define BLL, 11q.[4] |
Notably, no 1q21 abnormalities were found in myc-negative, 11q positive cases. [6][5]
Gene Mutations (SNV/INDEL)
- Studies suggest an overall unique mutational profile, with little to no overlap with commonly mutated genes in DLCBL and BL, respectively. Notably, recurrent mutations in BL such as ID3, TCF3, and CCND3 were not present. [5] [7]
- Mutations listed below where noted to be recurrent in BLL-11q cases. Bold genes have also been found recurrently mutated in DLCBL.
Recurrently mutated genes in BLL-11q with known mechanisms that may contribute to pathogenesis.
| Gene; Genetic Alteration | Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) | Prevalence (COSMIC / TCGA / Other) | Concomitant Mutations | Mutually Exclusive Mutations | Diagnostic Significance (Yes, No or Unknown) | Prognostic Significance (Yes, No or Unknown) | Therapeutic Significance (Yes, No or Unknown) | Notes |
|---|---|---|---|---|---|---|---|---|
| BTG2; variable potential LOF mutations
|
tumor suppressor gene via inhibition of CCND1 via pRb[5] | 4/11 cases[5]
|
none known | none known | unknown | unknown | unknown | |
| NFRKB **located in region of terminal deletion
|
gene associated with INO80 complex[7] | 4/15 cases[7] | none known | none known | unknown | unknown | unknown | NFRKB is within the terminal deletion region, so these mutations would result in a biallelic loss. [7]
|
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
Epigenomic Alterations
- KMT2A has been found to be duplicated and occasionally amplified in numerous cases of BLL-11q[3]
- functions to methylate histones[8]
- Found to have mutations in EP300, HIST1H1D, HIST1H2BC, CREBBP, KMT2C, EZH2, ARID1A, KMT2D[5]
Genes and Main Pathways Involved
- Given the notable variations in size of the duplicated and deleted regions of BLL-11q, pathogenesis appears to be complex and remains to be elucidated. Still, it is presumed to be a a product of dosage effects produced by the more varied proximal duplications and more consistent terminal deletions.[3]
- Genes found recurrently in minimal duplication region: IL10RA; TMPRSS4; SCN4B; AMICA1; MPZL3; CD3E; CD3D; UBE4A; ATP5L; KMT2A; TTC36, TMEM25, IFT46; ARCN1 [1] [3]
- Genes found recurrently in terminal deleted region: ETS1; FLT1; KCNJ5; C11orf45; TP53AIP1 [1] [3]
GENES with PROPOSED/KNOWN CANCER ASSOCIATIONS
| Gene; Genetic Alteration | Pathway | Pathophysiologic Outcome |
|---|---|---|
| IL10RA; Duplication | insulin receptor substrate-2/PI 3-kinase/AKT pathway[10] | increase survival of progenitor myeloid cells[10] |
| KMT2A; Duplication | methylation of histones (turns off genes)[8] | amplification noted to be associated with bulky BLL-11q tumors >20 cm, mainly located in the retroperitoneum[3] |
| USP2; duplication (found 1x) [3] | deubiquitinase known to target proteins such as MDM2 (udiquinates p53), MDM4, and CCND1[11] | increased degradation of p53 (less tumor suppressor) and more CCND1-->increased movement from G1 to synthesis[11] |
| NFRKB; deleted[7] | encodes a nuclear factor involved with the INO80 complex[7] | altered transcriptional regulation [7] |
Genetic Diagnostic Testing Methods
- Conventional cytogenetics (karyotyping) + FISH using MYC break-apart probe to rule out MYC translocation [4] [12]
- Chromosomal microarray analysis [5] [12]
Familial Forms
- None known
Additional Information
Put your text here
Links
References
- ↑ 1.0 1.1 1.2 1.3 Salaverria, Itziar; et al. (2014-02-20). "A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma". Blood. 123 (8): 1187–1198. doi:10.1182/blood-2013-06-507996. ISSN 0006-4971. PMC 3931189. PMID 24398325.CS1 maint: PMC format (link)
- ↑ Ferreiro, J. F.; et al. (2015-07-01). "Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern". Haematologica. 100 (7): e275–e279. doi:10.3324/haematol.2015.124305. ISSN 0390-6078. PMC 4486241. PMID 25795716.CS1 maint: PMC format (link)
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 Grygalewicz, Beata; et al. (2018-01-01). "The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS". American Journal of Clinical Pathology. 149 (1): 17–28. doi:10.1093/ajcp/aqx139. ISSN 0002-9173. PMC 5848380. PMID 29272887.CS1 maint: PMC format (link)
- ↑ 4.0 4.1 4.2 Asadbeigi, Sepideh N.; et al. (2020-09-08). "Burkitt-Like Lymphoma with 11q Aberration: A Case Report and Review of a Rare Entity". Case Reports in Hematology. 2020: e8896322. doi:10.1155/2020/8896322. ISSN 2090-6560. PMC PMC7495152 Check
|pmc=value (help). PMID 32963851 Check|pmid=value (help).CS1 maint: PMC format (link) - ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 Gonzalez-Farre, Blanca; et al. (2019-09). "Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma". Haematologica. 104 (9): 1822–1829. doi:10.3324/haematol.2018.207928. ISSN 0390-6078. PMC 6717587. PMID 30733272. Check date values in:
|date=(help)CS1 maint: PMC format (link) - ↑ Horn, Heike; et al. (2021-03). "A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas". American Journal of Surgical Pathology. 45 (3): 356–364. doi:10.1097/PAS.0000000000001613. ISSN 0147-5185. Check date values in:
|date=(help) - ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 Wagener, Rabea; et al. (2019-02-28). "The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma". Blood. 133 (9): 962–966. doi:10.1182/blood-2018-07-864025. ISSN 0006-4971. PMC 6396176. PMID 30567752.CS1 maint: PMC format (link)
- ↑ 8.0 8.1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=KMT2A. Missing or empty
|title=(help) - ↑ Bonetti, Paola; et al. (2013-09-26). "Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma". Blood. 122 (13): 2233–2241. doi:10.1182/blood-2013-01-475772. ISSN 0006-4971.
- ↑ 10.0 10.1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL10RA. Missing or empty
|title=(help) - ↑ 11.0 11.1 https://www.genecards.org/cgi-bin/carddisp.pl?gene=USP2. Missing or empty
|title=(help) - ↑ 12.0 12.1 Kim, Jee Ah; et al. (2021-11-01). "A Case of Burkitt-Like Lymphoma With 11q Aberration With HIV Infection in East Asia and Literature Review". Annals of Laboratory Medicine. 41 (6): 593–597. doi:10.3343/alm.2021.41.6.593. PMC PMC8203433 Check
|pmc=value (help). PMID 34108287 Check|pmid=value (help).CS1 maint: PMC format (link)
Notes
*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the Associate Editor or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.
Prior Author(s):
*Citation of this Page: “High grade B-cell lymphoma with 11q aberrations”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 02/12/2025, https://ccga.io/index.php/HAEM5:High_grade_B-cell_lymphoma_with_11q_aberrations.
Other Sections
Cancer Sub-Classification/Subtype
Burkitt-like lymphoma with 11q aberration
Definition/Description of Disease
Rare aggressive mature B-cell lymphoma
Synonyms/Terminology
myc-negative Burkitt-like lymphoma (mnBLL, 11q)[1]
non-myc Burkitt-like lymphoma (nmBLL)
BLL, 11q [2]
BLL-11q[3]HAEM5:Burkitt lymphoma
Clinical Implications
- Look for 11q aberration if Myc negative lymphoma with morphology reminiscent of BL, DLBCL, or HGBCL [3]
- Attend to associated chromosomal and mutational abnormalities of other aggressive B-cell lymphomas, ensuring their absence before diagnosis of BLL-11q, since BLL-11q may represent [2] [4] [5]
- BLL-11q patients treated with R-CHOP (DLBCL treatment) have a higher risk of relapse than those treated with traditional BL treatment [6] [7]
Tentatively appears to portend a better prognosis with high likelihood of years of remission [3] [8] [6][2]
- 100% 2 year event free survival in pediatric cohort[9]
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs named:1 - ↑ 2.0 2.1 2.2 Cite error: Invalid
<ref>tag; no text was provided for refs named:3 - ↑ 3.0 3.1 3.2 Cite error: Invalid
<ref>tag; no text was provided for refs named:6 - ↑ Wang, Jing; et al. (2021-03-16). "Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review". Open Medicine. 16 (1): 428–434. doi:10.1515/med-2021-0246. ISSN 2391-5463. PMC PMC7967281 Check
|pmc=value (help). PMID 33763601 Check|pmid=value (help).CS1 maint: PMC format (link) - ↑ Grygalewicz, Beata; et al. (2020-07-01). "Genetic progression of post-transplant Burkitt-like lymphoma case with 11q-Gain/Loss and MYC amplification". Cancer Genetics. 245: 1–5. doi:10.1016/j.cancergen.2020.05.001. ISSN 2210-7762. PMID 32531723 Check
|pmid=value (help). - ↑ 6.0 6.1 Cite error: Invalid
<ref>tag; no text was provided for refs named:5 - ↑ Rymkiewicz, Grzegorz; et al. (2018-05). "A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration". Modern Pathology. 31 (5): 732–743. doi:10.1038/modpathol.2017.186. ISSN 0893-3952. Check date values in:
|date=(help) - ↑ Cite error: Invalid
<ref>tag; no text was provided for refs named:9 - ↑ Au‐Yeung, Rex K. H.; et al. (2020-09). "Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4 ‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group". British Journal of Haematology. 190 (5): 753–763. doi:10.1111/bjh.16578. ISSN 0007-1048. Check date values in:
|date=(help)